NSEGeneral Updates1h ago · 31 Oct 2026, 08:14 pm
General Updates
Sun Pharmaceutical Industries Limited · SUNPHARMA
✦ AI SummaryFundraise
Sun Pharmaceutical Industries Limited has completed its postal ballot process, approving several special resolutions, including the Sun Pharma Employees Stock Option Plan 2026, provision of funds to the trust, and enhancement of borrowing limits.
Analysis Scores
Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Completion and Results of Postal Ballot dated 01 October 2026
Attachments (1)
📄pdf
Download →
SUNSEC_31102026201341_SEIntimationforVR_-_31_October_2026.pdf
View document text
Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050
31 October 2026
National Stock Exchange of India Limited BSE Limited
Scrip Symbol: SUNPHARMA Scrip Code: 524715
Completion and Results of Postal Ballot dated 01 October 2026
This is to inform you that the postal ballot process initiated pursuant to the notice dated 01 October 2026,
wherein the voting period commenced on 02 October 2026, has been concluded today, i.e., 31 October
2026.
Based on the Scrutinizer’s Report dated 31 October 2026, all the following Special Resolutions set out in
the Postal Ballot Notice have been approved by the members of the Company with the requisite majority.
Accordingly, the resolutions shall be deemed to have been passed on 31 October 2026, being the last date
specified for e-voting.
Item No. Particulars of Special Resolutions
Approval of the Sun Pharma Employees Stock Option Plan 2026 (“ESOP 2026”) and
Provision of Funds to the Trust
2. Approval of Secondary Acquisition of Equity Shares by the Trust
3. Approval for Extension of ESOP 2026 to Eligible Employees of Subsidiary Companies
4. Approval for Enhancement of Limits under Section 186 of the Companies Act, 2013
Approval for Enhancement of borrowing limit under Section 180(1)(c) of the Companies
Act, 2013
6. Approval for Creation of Security under Section 180(1)(a) of the Companies Act, 2013
Approval for Creation of Encumbrance over Shares Pursuant to Regulation 24(5) of the
SEBI Listing Regulations
The voting results pursuant to Regulation 44(3) of the SEBI Listing Regulations is submitted separately
in XBRL mode. The Scrutinizer’s Report is available on the website of the Company at
www.sunpharma.com.
For Sun Pharmaceutical Industries Limited
(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983
Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.
Reaching People. Touching Lives.